AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 327623 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary radiation therapy for stage I cases without randomization, followed or not by maintenance chemotherapy.
Number of subjects: 0
Study 327623 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantle field therapy for supradiaphragmatic stage II, followed if necessary by prophylactic infradiaphragmatic irradiation.
Number of subjects: 0
Study 327623 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abdominal irradiation for infradiaphragmatic stage II, followed by supradiaphragmatic prophylaxis if needed.
Number of subjects: 0
Study 327623 — intervention group
Group type: COMPARATOR
Intervention: Two regimens of maintenance chemotherapy for all stages II, randomized.
Number of subjects: 0
Study 327623 — intervention group
Group type: EXPERIMENTAL
Intervention: Two regimens of induction chemotherapy for stages III and IV, followed by maintenance chemotherapy.
Number of subjects: 0
Study 327623 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation of the icebergs for stage III cases.
Number of subjects: 0
Study 327623 — intervention group
Group type: EXPERIMENTAL
Intervention: Total irradiation for stages III or IV for centers desiring it.
Number of subjects: 0
Study 31553134 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 20 mg single dose
Number of subjects: 27
Study 31553134 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 40 mg single dose
Number of subjects: 27
Study 31553134 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 40 mg/d for 7 days (multiple doses)
Number of subjects: 27
Study 31553134 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 40 mg single dose under fasted and fed conditions
Number of subjects: 27
Study 31553134 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL)
Number of subjects: 27
Study 31696504 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (42 patients, 10M/32F, mean age 32.23 ± 10.3 years) treated with ciprofloxacin 400 mg twice a day and metronidazole 500 mg three times a day for one week, supplemented with probiotic mix (1 sachet twice a day for 10 days)
Number of subjects: 84
Study 31696504 — intervention group
Group type: COMPARATOR
Intervention: Control group (42 patients, 15M/27F, mean age 59.01 ± 11.3 years) received the same antibiotic treatment without the probiotic mix
Number of subjects: 84
Study 28108368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (SP)
Number of subjects: 616
Study 28108368 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus piperaquine (SP/PQ)
Number of subjects: 616
Study 28108368 — intervention group
Group type: COMPARATOR
Intervention: Passive control arm
Number of subjects: 616
Study 26415792 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum effective cuff inflating volume group (MC)
Number of subjects: 0
Study 26415792 — intervention group
Group type: COMPARATOR
Intervention: Routine care group (RC)
Number of subjects: 0
Study 24235233 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-derived antimicrobials (PDA) - trans-cinnamaldehyde (TC), carvacrol (CR), eugenol (EUG) at concentrations of 0.0, 0.25, 0.5, or 0.75%
Number of subjects: 0
Study 24235233 — intervention group
Group type: COMPARATOR
Intervention: Chlorine (200 mg/kg)
Number of subjects: 0
Study 24235233 — intervention group
Group type: COMPARATOR
Intervention: Wash water control (antibacterial-free)
Number of subjects: 0
Study 24235233 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-derived antimicrobials (PDA) - CR and EUG
Number of subjects: 0
Study 21470834 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute bowel toxicity
Number of subjects: 788
Study 21470834 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 788
Study 21470834 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 788
Study 21470834 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher prescribed dose
Number of subjects: 788
Study 21470834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment bladder symptoms
Number of subjects: 788
Study 19498009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrite-preserved red meat (PM)
Number of subjects: 28
Study 19498009 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh red meat (RM)
Number of subjects: 28
Study 19498009 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian (VEG) diet
Number of subjects: 28
Study 16686560 — intervention group
Group type: EXPERIMENTAL
Intervention: WIPP training program (8 weeks, 2 days per week)
Number of subjects: 21
Study 16686560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 14660997 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline summary, peer comparison performance feedback, and patient specific chart reminders
Number of subjects: 700
Study 14660997 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG CoA reductase inhibitors
Number of subjects: 700
Study 14660997 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 700
Study 14660997 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 700
Study 11182431 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group intervention (n=30)
Number of subjects: 60
Study 11182431 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 60
Study 8989069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (3 mg/kg daily orally) and placebo (100 mg/kg/daily orally)
Number of subjects: 85
Study 8989069 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (3 mg/kg daily orally) and flucytosine (100 mg/kg daily orally)
Number of subjects: 85
Study 8989069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 mg/kg daily orally) and placebo (100 mg/kg daily orally)
Number of subjects: 85
Study 1453306 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen immediately presurgically
Number of subjects: 60
Study 1453306 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo before surgery and 600 mg ibuprofen postsurgically
Number of subjects: 60
Study 1453306 — intervention group
Group type: COMPARATOR
Intervention: Placebo at both time periods
Number of subjects: 60
Study 2981982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin and vindesine (PVD)
Number of subjects: 167
Study 2981982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and VP‐16‐213 (PVP)
Number of subjects: 167
Study 2981982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with VP‐16‐213 and vindesine (PVPVD)
Number of subjects: 167
Study 30698812 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WHEY)
Number of subjects: 36
Study 30698812 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (SOY)
Number of subjects: 36
Study 30698812 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-enriched soy protein (SOY + LEU)
Number of subjects: 36
Study 31726649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle e-coaching application
Number of subjects: 95
Study 31726649 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 28632983 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Security® (COS) intervention
Number of subjects: 12
Study 26688233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiix-prothrombin time (Fiix-PT) monitoring
Number of subjects: 1156
Study 26688233 — intervention group
Group type: COMPARATOR
Intervention: PT-INR monitoring (Control)
Number of subjects: 1156
Study 23926117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin (E/S) + Niacin (N) (10/20 mg/day + titrated to 2 g/day)
Number of subjects: 577
Study 23926117 — intervention group
Group type: COMPARATOR
Intervention: Niacin (N) (titrated to 2 g/day)
Number of subjects: 577
Study 23926117 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe/Simvastatin (E/S) (10/20 mg/day)
Number of subjects: 577
Study 21874559 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg bilastine
Number of subjects: 21
Study 21874559 — intervention group
Group type: COMPARATOR
Intervention: 10 mg cetirizine
Number of subjects: 21
Study 21874559 — intervention group
Group type: EXPERIMENTAL
Intervention: bilastine 50 mg
Number of subjects: 21
Study 21874559 — intervention group
Group type: EXPERIMENTAL
Intervention: bilastine 20 mg
Number of subjects: 21
Study 21874559 — intervention group
Group type: COMPARATOR
Intervention: cetirizine 10 mg
Number of subjects: 21
Study 19903187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose LRPT 40 mg/day for 7 days coadministered with single-dose rosiglitazone 4 mg
Number of subjects: 12
Study 19903187 — intervention group
Group type: COMPARATOR
Intervention: Single-dose rosiglitazone 4 mg
Number of subjects: 12
Study 17257457 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac epolamine plaster (DHEP)
Number of subjects: 258
Study 17257457 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 258
Study 12939586 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment (various methods including vasoactive drugs, endoscopic therapy, combined therapy, balloon tamponade)
Number of subjects: 465
Study 12939586 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment
Number of subjects: 465
Study 12939586 — intervention group
Group type: COMPARATOR
Intervention: Variceal bleeding
Number of subjects: 465
Study 12939586 — intervention group
Group type: COMPARATOR
Intervention: Nonvariceal bleeding
Number of subjects: 465
Study 11466698 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU (150 mg/m(2) on Day 3) plus IFN‐alpha (12 million U/m(2) on Days 1‐3, Weeks 1, 3, and 5) every 7 weeks for a maximum of 6 cycles
Number of subjects: 275
Study 11466698 — intervention group
Group type: COMPARATOR
Intervention: BCNU alone (200 mg/m(2) on Day 1)
Number of subjects: 275
Study 9391690 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital-initiated thrombolysis
Number of subjects: 0
Study 9391690 — intervention group
Group type: COMPARATOR
Intervention: In-hospital thrombolysis
Number of subjects: 0
Study 8425660 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoglycemia (mean blood glucose 2.6 +/- 0.28 mM)
Number of subjects: 25
Study 8425660 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (mean blood glucose 6.3 +/- 0.89 mM)
Number of subjects: 25
Study 3299443 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 137
Study 3299443 — intervention group
Group type: COMPARATOR
Intervention: Blood Pressure Monitoring (BPM)
Number of subjects: 137
Study 28326881 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10^9 CFU/g each) for six weeks
Number of subjects: 60
Study 28326881 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 60
Study 28326881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26804247 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 78
Study 26804247 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 24937535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 441
Study 24937535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 23275013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lirukang Granule (LRKG) combined with psychological intervention
Number of subjects: 470
Study 23275013 — intervention group
Group type: COMPARATOR
Intervention: Lirukang Granule (LRKG)
Number of subjects: 470
Study 23275013 — intervention group
Group type: COMPARATOR
Intervention: Psychological intervention
Number of subjects: 470
Study 23275013 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 470
Study 21860279 — intervention group
Group type: EXPERIMENTAL
Intervention: 17α-hydroxyprogesterone caproate
Number of subjects: 671
Study 21860279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study 18281176 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating Procedure Device (RPD)
Number of subjects: 209
Study 18281176 — intervention group
Group type: COMPARATOR
Intervention: Conventional Syringe
Number of subjects: 209
Study 17070151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nitroprusside (NTP) 60 microg
Number of subjects: 98
Study 17070151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12859302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg i.v.
Number of subjects: 80
Study 12859302 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg i.v.
Number of subjects: 80
Study 10881824 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting operation with stabilization
Number of subjects: 58
Study 10881824 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting operation with cardiopulmonary bypass
Number of subjects: 58
Study 9085960 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.75, 1.0, or 1.5 mg bolus dose size)
Number of subjects: 102
Study 9085960 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (9, 12, or 18 mg)
Number of subjects: 102
Study 9085960 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 102
Study 9085960 — intervention group
Group type: COMPARATOR
Intervention: Morphine and Meperidine
Number of subjects: 102
Study 8448101 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4% with 20 micrograms epinephrine (2 mL)
Number of subjects: 20
Study 2891754 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg intravenous intra-operative dose)
Number of subjects: 190
Study 2891754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 29095521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol/Calcium
Number of subjects: 228
Study 29095521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol/Placebo
Number of subjects: 228
Study 29095521 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium/Placebo
Number of subjects: 228
Study 29095521 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-Placebo
Number of subjects: 228
Study 27815079 — intervention group
Group type: EXPERIMENTAL
Intervention: AnisEncap (enteric coated capsules of anise oil)
Number of subjects: 120
Study 27815079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 27815079 — intervention group
Group type: COMPARATOR
Intervention: Colpermin® (active control)
Number of subjects: 120
Study 27815079 — intervention group
Group type: EXPERIMENTAL
Intervention: AnisEncap
Number of subjects: 120
Study 24407551 — intervention group
Group type: EXPERIMENTAL
Intervention: RXU (RelyX Unicem 3MESPE-RXU) without enamel etching
Number of subjects: 34
Study 24407551 — intervention group
Group type: EXPERIMENTAL
Intervention: RXU + E (RelyX Unicem 3MESPE-RXU with selective enamel etching)
Number of subjects: 34
Study 24407551 — intervention group
Group type: COMPARATOR
Intervention: RXU
Number of subjects: 34
Study 24407551 — intervention group
Group type: COMPARATOR
Intervention: RXU + E
Number of subjects: 34
Study 23270200 — intervention group
Group type: EXPERIMENTAL
Intervention: tazarotene foam 0.1%
Number of subjects: 97
Study 23270200 — intervention group
Group type: COMPARATOR
Intervention: vehicle foam
Number of subjects: 97
Study 23270200 — intervention group
Group type: COMPARATOR
Intervention: no foam (blank patch)
Number of subjects: 97
Study 15946913 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 54
Study 15946913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 12006420 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg twice daily)
Number of subjects: 42
Study 12006420 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily)
Number of subjects: 42
Study 12006420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 9614778 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (4 micrograms/kg/minute, Group A)
Number of subjects: 20
Study 9614778 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (4 micrograms/kg/minute, Group B)
Number of subjects: 20
Study 7897035 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset dysthymia
Number of subjects: 187
Study 7897035 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 187
Study 7897035 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic major depression
Number of subjects: 187
Study 2515593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g b.i.d.
Number of subjects: 16
Study 2515593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 356252 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled RS 7540 (40 mg)
Number of subjects: 12
Study 356252 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled RS 7540 (20 mg)
Number of subjects: 12
Study 356252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31899185 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 29945404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pi needle
Number of subjects: 278
Study 29945404 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 278
Study 27217047 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus with azole antifungal agents (AZ)
Number of subjects: 24
Study 27217047 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus without azole antifungal agents (AZ)
Number of subjects: 24
Study 25015020 — intervention group
Group type: EXPERIMENTAL
Intervention: Physics forceps
Number of subjects: 54
Study 25015020 — intervention group
Group type: COMPARATOR
Intervention: Universal extraction forceps
Number of subjects: 54
Study 22250191 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective BRAF inhibitors
Number of subjects: 2
Study 22250191 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic and anti-inflammatory treatment (e.g., etoricoxib)
Number of subjects: 2
Study 22250191 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction of BRAF inhibitor
Number of subjects: 2
Study 20531011 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 245
Study 20531011 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 245
Study 17645554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylurea treatment in addition to dietary regulation and increased exercise
Number of subjects: 154
Study 17645554 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 154
Study 15955935 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 1,500 mg/day
Number of subjects: 593
Study 15955935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 150 mg/day
Number of subjects: 593
Study 15955935 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) 600 mg/day
Number of subjects: 593
Study 11839708 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline injection plus heater probe thermocoagulation
Number of subjects: 1144
Study 10405498 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall (single dose)
Number of subjects: 84
Study 10405498 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (2 daily doses)
Number of subjects: 84
Study 7749423 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHO diet of 10.52 +/‐ 0.57 g/kg body mass/day
Number of subjects: 8
Study 7749423 — intervention group
Group type: COMPARATOR
Intervention: Normal CHO intake of 6.15 +/‐ 0.23 g/kg body mass/day
Number of subjects: 8
Study 2309227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural bupivacaine (20 ml of 0.25% bupivacaine for 48 hours)
Number of subjects: 54
Study 2309227 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine intercostal block
Number of subjects: 54
Study 2309227 — intervention group
Group type: COMPARATOR
Intervention: Cryofreezing of intercostal nerves
Number of subjects: 54
Study 398485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (50 mg/kg/day in 4 divided doses for 5 days)
Number of subjects: 54
Study 398485 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (50 mg/kg/day in 3 divided doses for 5 days)
Number of subjects: 54
Study 31808786 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational treatment about opioids
Number of subjects: 0
Study 31808786 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 30714749 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT) plus treatment as usual (TAU)
Number of subjects: 181
Study 30714749 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 181
Study 28345762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (LCD) (≤50 g/d)
Number of subjects: 10
Study 28345762 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet (HCD) (≥250 g/d)
Number of subjects: 10
Study 25087012 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychosocial intervention
Number of subjects: 50
Study 24151390 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine (10 mg every 8 hours for 2 weeks)
Number of subjects: 197
Study 24151390 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% isotonic saline for 2 weeks)
Number of subjects: 197
Study 21208340 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy hysterectomy (≤5 cm incision)
Number of subjects: 98
Study 21208340 — intervention group
Group type: COMPARATOR
Intervention: Standard abdominal hysterectomy (>6 cm incision)
Number of subjects: 98
Study 19751822 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (vitamins E and C)
Number of subjects: 20
Study 19751822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19751822 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma ascorbic acid concentrations
Number of subjects: 20